XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Revenues $ 2,225.1 $ 1,860.1 $ 1,831.4
Operating expenses:      
Salaries and benefits 644.3 550.3 550.0
Supplies 636.4 538.4 507.9
Professional and medical fees 230.0 191.4 154.8
Lease expense 90.6 87.4 85.6
Other operating expenses 132.4 112.8 109.3
Cost of revenues 1,733.7 1,480.3 1,407.6
General and administrative expenses 104.0 97.1 88.6
Depreciation and amortization 98.8 94.8 76.5
Income from equity investments (11.3) (10.8) (10.2)
Loss (gain) on disposals, net 2.2 5.7 (4.4)
Transaction and integration costs 39.8 23.2 19.0
Impairment charges 0.0 33.5 7.9
Grant funds (37.9) (46.2) 0.0
Loss on debt extinguishment 9.1 0.0 11.7
Litigation settlement 0.0 1.2 0.2
Other income (15.5) (1.7) (1.4)
Total operating expenses 1,922.9 1,677.1 1,595.5
Operating income 302.2 183.0 235.9
Tax receivable agreement expense 0.0 0.0 (2.4)
Interest expense, net (221.0) (201.8) (178.9)
Income (loss) before income taxes 81.2 (18.8) 54.6
Income tax expense (benefit) 10.5 (20.1) 9.5
Net income 70.7 1.3 45.1
Less: Net income attributable to non-controlling interests (141.6) (117.4) (119.9)
Net loss attributable to Surgery Partners, Inc. (70.9) (116.1) (74.8)
Less: Amounts attributable to participating securities (10.3) (39.5) (35.7)
Net loss attributable to common stockholders $ (81.2) $ (155.6) $ (110.5)
Net loss per share attributable to common stockholders - basic (in USD per share) [1] $ (1.12) $ (3.19) $ (2.29)
Net loss per share attributable to common stockholders - diluted (in USD per share) [1] $ (1.12) $ (3.19) $ (2.29)
Weighted average shares outstanding - basic (shares) [1] 72,427 48,776 48,280
Weighted average shares outstanding - diluted (shares) [1] 72,427 48,776 48,280
[1] The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in those periods.